Psychotropic Drug Prescription in Children and Adolescents: Approved Medications in European Countries and the United States.

Details

Serval ID
serval:BIB_9623F2827944
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Psychotropic Drug Prescription in Children and Adolescents: Approved Medications in European Countries and the United States.
Journal
Journal of child and adolescent psychopharmacology
Author(s)
Smogur M., Onesanu A., Plessen K.J., Eap C.B., Ansermot N.
ISSN
1557-8992 (Electronic)
ISSN-L
1044-5463
Publication state
Published
Issued date
03/2022
Peer-reviewed
Oui
Volume
32
Number
2
Pages
80-88
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Objectives: The decision to prescribe a medication and the choice of which one are often complex, particularly in the field of child and adolescent psychiatry where evidence is scarce. The aim of this review is to provide a synthesis of psychotropic drugs approved in children and adolescents for psychiatric indications in several countries. Methods: All psychopharmacological treatments used in child and adolescent psychiatry, approved by at least one regulatory agency from Switzerland, the United Kingdom, France, the European Union, or the United States, were considered. A comprehensive review of the summaries of product characteristics was performed. Results: A total of 143 psychotropic drugs were included: 47 anxiolytics/hypnotics, 45 antidepressants, 37 antipsychotics, 10 medications for attention-deficit/hyperactivity disorder (ADHD), and 4 mood stabilizers. Only a few of these drugs were approved for use in children or adolescents (38%) at least for a single psychiatric diagnosis in at least one country. The therapeutic class with the lowest rate of approved status was antidepressants (20%), followed by mood stabilizers (25%), anxiolytics/hypnotics (28%), antipsychotics (57%), and medications for ADHD (100%). Important differences in approved diagnoses, ages, and doses were observed between regulatory agencies. Tables presenting drugs for approved diagnoses based on age and regulatory agencies are presented in this article. Drugs classified by regulatory agencies, with complete data on diagnoses, ages, doses, pharmaceutical forms, and particular restrictions, are presented as Supplementary Material. Conclusion: This article provides an overview to prescribers with respect to the approved medications in children and adolescents in selected European countries and the United States.
Keywords
Adolescent, Anti-Anxiety Agents/therapeutic use, Anticonvulsants/therapeutic use, Antidepressive Agents/therapeutic use, Antimanic Agents/therapeutic use, Antipsychotic Agents/therapeutic use, Child, Drug Prescriptions, Humans, Hypnotics and Sedatives/therapeutic use, Pharmaceutical Preparations, Psychotropic Drugs/therapeutic use, United States, European countries, approved indications, children and adolescents, psychiatry, psychotropic drugs
Pubmed
Web of science
Create date
12/02/2022 15:09
Last modification date
27/04/2022 6:37
Usage data